Atrys Health

Atrys

Contact information

Atrys Health
Cristina Pérez Sánchez
C/ Velázquez 24, 4º
Madrid
Madrid
917819465
915776744
Areas of activity
  • A. Health Biotechnology
  • A. Health Biotechnology
  • Therapeutic areas
  • A. Health Biotechnology
  • Therapeutic areas
  • Oncology
  • A. Health Biotechnology
  • Therapeutic areas
  • Blood and lymphatic system
  • A. Health Biotechnology
  • Areas of activity
  • A. Health Biotechnology
  • Areas of activity
  • In vitro diagnostics
  • A. Health Biotechnology
  • Areas of activity
  • Diagnostic imaging
  • D. Services
  • D. Services
  • R&D services
  • D. Services
  • R&D services
  • Biotechnolgy kits
  • D. Services
  • R&D services
  • Genomics
  • D. Services
  • R&D services
  • Proteomics
Commissions

Atrys is a biomedical company engaged in the development of new tools for the study of predictive and personalized oncology and inflammatory diseases. It has a multidisciplinary team of physicians and scientists with a solid career in the field of diagnosis, therapy and biomedical research, including the study of stem cells. It has three areas of activity constantly innovating: Care in Diagnosis / Prognosis, Translational Research covering the gap between basic and clinical research and advanced radiotherapy treatments.

Products and services

Atrys main business areas are:

  • Routine diagnosis and prognosis: we provide an integrated analysis of tissue and molecular phenotypes for cancer and allied diseases, using novel technologies to predict outcome and customize treatment for each patient
  • Translational research: we develop algorithms based on molecular and morphometric signatures that define the specific individual tumor phenotype. This will allow us to identify those patients most likely to benefit from different treatment modalities.
  • Treatment: we implement novel image-guided, intensity modulated single dose radiotherapy protocols targeting the tumor while completely excluding surrounding normal tissues. The aim is improving treatment-planning as well as delivery accuracy and speed, thus enhancing patient throughput, therapeutic benefit and safety.

The main advantage of integrating these three activities is the ability to evolve rapidly by re-distributing know-how and resources between areas. The integration allows for commercial synergies that offer competitive advantages by having a diagnostic-therapeutic development pipeline.

Translational R&D strategy:

  • Apply Molecular and Systems Pathology to study cancer through object-oriented image analysis, pattern recognition, and quantitative biomarker multiplexing
  • Validate pre-clinical models by pathway analysis and Molecular and Systems Pathology
  • Define therapeutic end-points, resistance mechanisms, and markers of tumor progression in order to optimize clinical trials
  • Apply artificial intelligence and mathematical modeling to develop decision-making algorithms to improve clinical management

In clinical trials, through the application of Molecular and Systems Pathology:

  • Facilitate patient selection according to drug-response
  • Optimize clinical trials: positive impact in cost and time savings
  • Provide reproducibility, and consistency of clinical trial results / measurements
  • Maximize the likelihood of success for drug regulatory approval